It is now well established that gene expression profiling using DNA microarrays can provide novel information about various types of hematological malignancies, which may lead to identification of novel diagnostic markers. However, to successfully use microarrays for this purpose, the quality and reproducibility of the procedure need to be guaranteed. The quality of microarray analyses may be severely reduced, if variable frequencies of nontarget cells are present in the starting material. To systematically investigate the influence of different types of impurity, we determined gene expression profiles of leukemic samples containing different percentages of nonleukemic leukocytes. Furthermore, we used computer simulations to study the effect of different kinds of impurity as an alternative to conducting hundreds of microarray experiments on samples with various levels of purity.
Introduction
The recent introduction of microarrays has revolutionized the biological research field. [1] [2] [3] Whereas previously many studies focused on the expression of one gene in one specific cell type, the introduction of microarray technology has given researchers the opportunity to study the expression of thousands of different genes (ie the gene expression profile) in various cell types within a short period of time. [4] [5] [6] [7] Accordingly, microarrays can be used to distinguish different cell types based on their gene expression profile. In the field of oncology, the use of microarrays has led to new insights about etiology and pathofysiology of malignancies. 6, 8, 9 For various types of cancer, this has led to the proposition of novel subtypes, which might have implications for prognosis and treatment. [10] [11] [12] As a consequence, gene expression profiling using microarray analyses is increasingly seen as a possible diagnostic tool. [13] [14] [15] In the field of hematological malignancies, several seminal papers have demonstrated that the use of microarrays indeed may provide novel information at diagnosis. 16, 17 This type of information may lead to the development of novel diagnostic tools in the future.
One can envision two different ways in which microarray data can be used to identify novel markers with possible diagnostic relevance. First, comparisons between malignant and nonmalignant sample data may result in a list of differentially expressed genes, which are potential cancer-associated markers. These may then be used as diagnostically relevant markers. Second, the microarray data as a whole may be used directly to classify tissue samples as malignant or nonmalignant. In both cases, successful use of microarrays for studying malignant diseases will be dependent on the quality and reproducibility of the entire microarray analysis procedure. 18 This means that nonspecific variation (both biological and technical) should be minimized as much as possible. This variation can be influenced by various parameters, for example, the procurement and storage of the clinical cancer sample, the purity of the collected material, the technique used to extract RNA, the procedure to label the RNA, the type of microarray used and the interpretation of the gene expression data. 19, 20 Recently, guidelines (MIAME, http://www.mged.org/) have been proposed to assure the reproducibility, and hence comparability, of microarray experiments. These guidelines mainly concentrate on the experimental design, RNA extraction and labeling techniques, and the data mining process.
In most cases, investigators are interested in the expression profile of the tumor per se. Although it is possible that other cell types interacting with the tumor (eg a T-cell infiltrate in nonHodgkin's lymphomas) provide clinically relevant information, in which case one may decide to forego purification. However, in all other cases, the purity of the sample used is an important aspect influencing the quality of microarray experiments. Intuitively, many investigators have recognized this as an important parameter, [21] [22] [23] but very few studies have systematically studied this problem. For leukemias, our previous study on diagnosis-relapse comparison in precursor B-ALL has superficially dealt with this issue. 24 Here, we present a systematical investigation towards the problem of differential tumor load between two groups of clinical samples to be compared within one study, for example, malignant and nonmalignant samples.
Theoretically, sample impurity can influence measured expression differences in three ways, depending on the type of impurity present in either group:
Random impurity: if each sample contains some amount of nontumor cells variable in nature, genes expressed in these cells will give rise to expression levels significantly higher than background. As this random impurity is independent of the signal of the expressed genes in the pure tumor sample, random impurity only increases the variance for those genes, effectively decreasing their signal-to-noise ratio. The statistical methods used to determine significant differential expression should be designed in such a way that they are robust enough to handle this type of noise. Therefore, a priori no significant differences between the average expression levels of the groups are to be expected for genes expressed in nontumor cells. The influence of this noise may at most decrease the number of significantly differentially expressed genes found between samples. This type of impurity usually occurs in any microarray experiment for which samples are collected from identical tissue types, at identical locations in the body, under similar circumstances, and constitutes normal biological variation. Fixed impurity: if samples in both groups contain the same proportion of identical nontumor cells, this may alter the expression levels of genes consistently. Since this alteration is independent of the grouping, it decreases the differences between group means of the altered genes, that is, the signal. Effectively, this decreases only their signal-to-noise ratio. Consequently, at most the percentage of true positives is decreased (leaving the false positive and negative percentages unchanged). An example of this type of impurity is a constant percentage of contaminating T-lymphocytes in precursor-B-ALL. Group-specific impurity: samples in both groups may contain different types of nontumor cells, or one group may contain nontarget cells whereas the other group does not. When the type of nontumor cell is specific to one group, this may lead to significant differences in expression between groups for certain genes. This form of impurity can occur in cases where samples are collected from different tissue types, at different locations in the body or in different circumstances (eg diagnosis/relapse). An example of this type of impurity is the case of different levels of nonleukemic cells in a leukemia, for example, normal immature myeloid cells in a precursor B-ALL sample. Another example is when precursor-B-ALL samples taken from peripheral blood (with contaminating T-lymphocytes) are compared with samples taken from bone marrow (containing contaminating myeloid cells).
Of course, in practice different types of impurity will be present concurrently, and so will have a combined influence on the analysis.
In this article we address different aspects of purification of cell samples for microarray experiments. First we analyzed expression profiles of samples in which we introduced groupspecific impurity by contaminating tumor samples with increasing amounts of normal blood leukocytes. Next, we analyzed two leukemia samples, each with and without purification, demonstrating how purification influences microarray analysis. Additionally, we performed computer simulations (in silico experiments) on a number of two-group microarray experiments using different numbers of microarrays per group and different percentages of contaminating cells. We have used computer simulations as an alternative to conducting hundreds of microarray experiments on samples with different levels of purity, as this is costly and extremely labor-intensive. Based on our results we propose guidelines for purification of cell samples in microarray experiments, that aim to focus on the malignant cells only.
Materials and methods

Sample material
Tumor material of three patients was used in this study. One patient was diagnosed with chronic myeloid leukemia (CML); the tumor load was estimated to be B100% (ie over 98%) based on cell count. The samples of two patients with CD7 þ T-cell 
MACS purification and flow cytometric analysis
Half of each of the two CD7-positive T-ALL samples was enriched to obtain tumor loads of more than 95%, by staining with CD7-PE (Becton Dickinson Biosciences, San Jose, CA, USA), subsequently incubating with anti-PE Microbeads (Miltenyi Biotech, Gladbach, Germany) according to the manufacturer's protocol and finally separating with program POSSEL on the AutoMACS (Miltenyi Biotech) according to the manufacturer's protocol. Directly after purification the samples were analyzed with CD7-PE (Becton Dickinson Biosciences), CD5-APC (Becton Dickinson Biosciences) and CD2-FITC (Coulter Corporation, Miami, FL, USA) on the flow cytometer.
RNA extraction, labeling and hybridization to microarray
Total RNA was extracted with the use of the Qiagen RNeasy kit (Qiagen, Valencia, CA, USA); purity and quality was assessed by RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). None of the samples showed degradation (ratio of 28S ribosomal RNA to 18S ribosomal RNA of at least 2) or contamination of DNA. In total, 1 mg of RNA was used for cDNA synthesis and cRNA synthesis. In total, 15 mg cRNA was hybridized to the HG-U133A GeneChip oligonucleotide microarray (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's protocol (701025 Rev 5). Staining, washing and scanning procedures were carried out as described in the GeneChip Expression Analysis technical manual (Affymetrix).
Data analysis
In order to examine the quality of the different arrays, measured intensity values were analyzed using the GeneChip Operating Software (Affymetrix). The scaling factor (o3SD), percentage of probesets present (27.2-33.1%), noise (2620-2900), background (66.57-76.54) and ratio of GAPDH 3 0 to 5 0 (o1.4), all indicated high quality of samples and an overall comparability. Microarray data were quantile normalised 25 and background signal was removed using robust multichip analysis (RMA). 26 Arrays were compared based on the perfect match (PM) probe intensity levels only, 26 by performing a per-probe set two-way analysis of variance (ANOVA, with factors 'probe' and 'array'). This results both in average expression levels for each probe set and P-values. The latter were adjusted for multiple testing using Šidák step-up adjustment 27 and all probe sets with adjusted Pvalues smaller than 0.05 were considered significantly differentially expressed. All raw microarray data are available at http:// franklin.et.tudelft.nl/.
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Computer simulations
To learn about the effect of impurity on the analysis of microarray datasets, we performed a number of simulations. Expression values were simulated for n microarrays, where nA{10, 20, 40, 100}. Each microarray contained p ¼ 1000 genes. The microarrays fell into two equally sized groups, A and B (eg corresponding to 'diagnosis' and 'relapse'). On arrays in group A, none of the genes were highly expressed; on arrays in group B, 50 genes were highly expressed, simulating differential expression between groups A and B in the target cell type. Levels of both random and group-specific impurities were simulated by expressing 50 (random and fixed, respectively) additional genes at f ¼ 0-100% of the expression of a truly expressed gene, leading to simulated target cell type loads ranging between 100% (target cell-specific genes differentially expressed at 100%, impurity-specific genes at f ¼ 0%) and 50% (target cell-specific genes differentially expressed at 100%, impurity-specific genes at f ¼ 100%). For details of the simulation, see Appendix A.
A number of well-known techniques for comparing and classifying microarray data was applied to the simulated data sets: the t-test, 27 significance analysis of microarrays (SAM, 28, 29 ) and prediction analysis of microarrays (PAM, 30 ):
In the t-test analysis, an individual test was applied to each gene to find differential expression, yielding a t-statistic. Its null distribution was estimated, for each gene, by randomly permuting group labels, A and B, 1000 times and calculating t-statistics for that gene. The P-value was set to the relative number of permutations for which a larger t-statistic was found than for the original group labeling. Šidák step-up adjustment was then applied to the P-values found, and all genes with an adjusted P-valuep0.05 were counted as significantly differentially expressed. For SAM, thresholds D were tried from the range [0.01, 0.02, y, 0.10, 0.20, y, 2.50, 2.75, y, 5.00]. The D giving the lowest positive false discovery rate (pFDR 31 ) was chosen, and all genes with a difference larger than D in SAM statistics between the two groups were called significantly differentially expressed. PAM was applied with the same range for the threshold D as used for SAM. No per-group scaling was used. The optimal D was found by 10-fold cross-validation. Besides a crossvalidation error, PAM gives a list of genes useful for classification. Note that this does not entail that these genes need to be significantly differentially expressed. It also does not mean that PAM uses all genes that are significantly differentially expressed.
All simulations were repeated 10 times, with mean and standard deviations indicated in figures. Simulations were performed in the MATLAB programming environment (The Mathworks, Natick, MA, USA) using software developed by the authors. This software can be downloaded from http:// franklin.et.tudelft.nl/.
Results
Impurities introduced in a leukemic sample: CML mixed with normal mononuclear cells
To systematically investigate the influence of impurities in DNA microarray analyses, we used cells derived from a patient with newly diagnosed CML (target) mixed with blood mononuclear cells (nontarget) of a healthy control, introducing group-specific impurity. RNA was extracted from five samples with a tumor load of 100% (twice), 75%, 50% and 25%. We identified the expression profiles of the different samples and compared the profiles of contaminated samples to the samples with 100% tumor load.
Comparison between the two independently processed 100% CML samples (CML1 and CML2) showed no significantly differentially expressed probesets, that is, the technical variation between the two experimental procedures does not lead to erroneous findings. This is in accordance with previous experience concerning independent processing of identical samples (unpublished data from our and other laboratories).
As shown in Figure 1a , many probesets were significantly differentially expressed between the pure and contaminated samples. These could have led to false identification of genes involved in tumorigenesis in CML. For some genes the derivation from contaminating cells may be obvious (eg wellknown lineage specific genes), yet many other genes are not known to be associated with nonmyeloid cell lineages and are therefore hard to assign as resulting from impurities. The full list of genes can be found in Supplementary Table 1 .
When the tumor load was lowered from 100% to 75%, 31 probesets were identified as significantly differentially expressed. Among these were erythrocyte specific genes (eg hemoglobins), genes encoding for growth factors (eg granulin) and genes involved in cell signaling (IL-8, monocyte chemotactic protein).
A tumor load of 50% showed 84 significantly differentially expressed probesets as compared to 100% CML. Genes up-or downregulated in this comparison contained genes encoding for B-cell specific proteins (CD83, CD48), NK-cell-specific proteins (killer cell lectin-like receptor) and MHC class II.
If the tumor cells only accounted for 25%, 134 probesets were up-or downregulated as compared to the 100% tumor sample. Genes found in this analysis included B-cell specific genes (CD83, CD48, immunoglobulins), erythrocyte-specific genes (hemoglobulin, ferritin), genes specific for dendritic cells (dendritic cell-associated C-type lectin-1), NK-cell-specific genes (killer cell lectin-like receptor subfamily B) and genes encoding for cell signaling (small inducible cytokine A7, IL-8, monocyte chemotactic protein 3).
The sets of probesets found to be differentially expressed in the various comparisons overlap to a large degree (see Supplementary Figure 1 ): 24 of the 31 and 52 of the 84 probesets can be found in the 134. The lack of full overlap is caused by random fluctuations, causing some probesets just significantly differentially expressed at low impurity levels, to be missed at higher impurity levels.
With increasing numbers of nontarget cells, the level of expression of the vast majority (108 of the 134) of the significantly differentially expressed probesets increases monotonically from CML (100%) to CML (25%) (Figure 1b) . This clearly indicates that the identified probesets correspond to the impurity introduced.
Naturally occurring impurities in leukemia: purified vs nonpurified T-ALL
To further investigate the influence of purification on expression profiles, we compared two T-ALL samples before purification and after purification (Figure 2a) . For both individual T-ALLs, the gene expression profiles of the purified and Purification of tumor cells in DNA microarray studies D de Ridder et al nonpurified samples were compared. This resulted in a large number of probesets that differed significantly (Figure 2b ). In T-ALL1 108 probesets (among which B-cell specific genes) were significantly differentially expressed between purified (more than 95%) and nonpurified (89%) tumor cells. In T-ALL2 the number of significantly differentially expressed probesets between the purified (more than 95%) and nonpurified (62%) samples was 178. Potentially, these could incorrectly be labeled as important in the tumorigenesis of T-ALL. 
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We realized that the use of antibodies could potentially activate the cells of interest leading to an altered gene expression profile. In our hands, negative selection usually does not lead to the level of purity required (490%, as we show later on in this report) to make appropriate statements on individual samples. Therefore, positive selection needs to be used. In order to avoid activation problems the following precautions were taking: essentially all purification steps were done cold (41C), which diminishes activation of cellular signaling pathways, antibodies against strongly activating antigens (Such as C2, CD3, TCR, BCR) were not used, and the samples to be compared (eg diagnosis vs relapse) were purified with the same antibody at the same time in parallel experiments. Together, these precautions should largely diminish effects of the antibody used on gene expression profiles, and if they occur, they are expected not to be detected as differential effects.
Computer simulations
Statistical analysis plays an important role in analysis of microarray data. Various types of algorithms and statistical tools are used to analyze the data. Here we employed three commonly used tools: (1) Student's t-test, which assumes a normal distribution of the data, where one sets a P-value as threshold for identification of statistically relevant genes. (2) SAM (significance analysis of microarrays), a gene selection method that identifies significantly differentially expressed genes based on permutation tests. (3) PAM (prediction analysis of microarrays), a classification tool with built-in predictive gene selection. In order to investigate the issue of impurity from a theoretical point of view, we simulated a number of microarray experiments in silico, considering both random impurities as seen in the processing of identical samples and group-specific impurities as seen in the comparison of malignancies with different fractions of tumor cells.
Computer simulations: random impurities Figure 3 depicts simulation results for random impurities. It is clear that sample size n played a large role. For n ¼ 10, gene selection failed. The t-test selected no genes, whereas SAM and PAM selected a small number of genes, of which a large percentage consisted of false positives. For n ¼ 100, gene selection worked well. The t-test and SAM both found small numbers of false positives; SAM had the advantage for n ¼ 20 and 40, but for n ¼ 100 found slightly more false positives. PAM found no false positives for n ¼ 40 and 100, but selected a smaller number of genes on which to base classification. Purification of the T-ALL1 sample by means of CD7 expression and MACS beads. The effects of purification on gene expression profiling. (a) FACS profiles before purification (tumor load 89%) and after purification (tumor load 98%). (b) Comparison of gene expression profile of purified and nonpurified T-ALL samples of the same patient, for T-ALL1, 89% tumor load before purification and T-ALL2, 62% tumor load before purification. Both T-ALLs were more than 95% CD7 þ after purification.
Purification of tumor cells in
Of course, the specific n for which these sample size effects shown here to occur, depends on the number of genes on the array. It is in the medium sample size area (n ¼ 20) that the effect of random impurities is seen most clearly. Gene selection on pure samples here produced a relatively small number of true positives and a small number of false positives. As hypothesized, the main effect of random impurities on gene selection (t-test, SAM) is that, for large amounts of nontarget cells, the number of truly significantly differentially expressed genes found slightly decreased; however, the number of false positives found did not increase significantly. Thus, the methods are robust to noise. The same holds for the classification results of PAM.
Computer simulations: group-specific impurities
Simulation results for group-specific impurities are displayed in Figure 4 . The same sample size effects as for random impurities were found here: n ¼ 10 is too small, n ¼ 40 gave reasonable results and n ¼ 100 good results on pure samples. In between these, the gene selection methods (t-test, SAM) found approximately the same numbers of true positives as were found with random impurities. However, as hypothesized, the number of false positives here increased with increasing group-specific impurity. For low impurity levels (up to 90% target cell type load), the effect was still relatively small. For higher levels, the effect was quite dramatic. At a purity of 50%, for n ¼ 100 as many false positives were found as true positives: that is, all simulated false positives were identified.
The classification performances of PAM were good, even for relatively small numbers of microarrays per group (n ¼ 20). PAM does not suffer from group-specific impurity, because it selects genes based on classification performance only, regardless of whether they stem from target or nontarget cells. However, many of the genes PAM selected were false positives. As can be seen in Figure 4 , a tumor load of less than 75% can lead to up to 25% erroneously identified genes. A tumor load of more than 90% leadsto the identification of less than 5% falsepositive genes.
Discussion
We investigated the issue of differential tumor load and impurities both from an experimental and a computer simulation point of view. In order to conduct a meaningful microarray experiment, the population of interest needs to be accurately defined. 32 In oncological studies, generally the population of interest will correspond to a single cell type, although circumstances exist in which nontumor cells provide additional information about tumor characteristics and patient response. For example, the presence of T-cells surrounding breast tumors may be indicative of the level of the immunological response and hence may have prognostic value. However, in most cases, The most obvious way to evade impurities in a microarray experiment is purification of the starting population. In leukemia, this is relatively easy to perform, since leukemic cells are clearly distinguishable from nonmalignant cells by their immunophenotype. [33] [34] [35] Previously, we purified precursor-B-ALL samples on the expression of CD19 and CD34, which lowered the number of significantly differentially expressed probesets in a comparison between diagnosis and relapse. 24 Here, we have specifically focused on the influence of purification on the outcome of microarray experiments, specifically in cases where two (or more) groups are present and gene selection or classification has to be performed. Three possible types of sample impurity can influence microarray data analysis. Random impurities pose a minor problem, as the methods employed in our simulations appeared to be sufficiently robust to handle the noise these impurities introduce. Fixed, identical impurities in all groups (not simulated) may lead to a decrease in true positives, but not to finding false positives. Finally, group-specific impurities, which are a problem in specific research settings, were shown to lead to unreliable results for low purity samples in our simulations: although the number of true positives remained unchanged with increasing purity, the number of false positives dramatically decreased. Our laboratory experiments verified this: group-specific impurities indeed influenced analysis results, and this influence increased with an increase in impurity. This may lead to the incorrect identification of potential diagnostic markers.
Our findings can in principle be applied to other microarray experiments as well, for instance to solid tumors. Although purification of solid tumors is hard to perform, attempts to decrease nontarget cells have been made. The best way to isolate target cells in solid tumors or solid tissue in general is morphological identification by experienced pathologists. 36 A disadvantage of morphological identification is the inter-and intraindividual variation between different pathological investigations. [37] [38] [39] This can partly be corrected for by immunohistochemistry and determination of additional markers by PCR or cytogenetic techniques. [40] [41] [42] [43] Another aspect in purification of tumor cells from solid tissues is the direct contact with nontarget cells. In contrast to leukemic cells in blood and bone marrow, solid tumors are well attached to their surrounding nonmalignant cells by all kinds of cellular interactions. [44] [45] [46] Since tumor cells are usually dispersed throughout the tissue of interest, pure cell samples are often difficult to obtain.
In order to overcome the problem of the presence of nontarget cells in solid tissues, several groups have tried to diminish the influence of impurities by manipulating the resulting data sets. [47] [48] [49] In one of these studies, cells with different gene expression profiles were used in a linear model in order to predict their influence on the overall gene expression profile. 49 Another study performed by Lu et al 49 mainly focused on genes already known to have a function in cell cycle. However, these approaches are not readily suitable to discover new genes in specific circumstances or when the amount and nature of contaminating cells are unknown.
Based on our findings we propose the following guidelines to reduce the influence of contaminating cells in leukemia research as much as possible and to enable good comparisons between microarray experiments performed in different experiments. The simulation results indicate that the tumor load in leukemic samples should exceed 90%, provided the right statistical tools are used. At lower tumor loads, purification to more than 90% is needed, but should then be done for all samples under study, to make comparisons possible. Especially, if data from individual samples are analyzed in detail, purification is essential. Classification of samples is less susceptible to contamination problems, but here too, better results can be obtained with high tumor load, specifically when sample sizes are low (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (Figures 3d and 4d) . Purification should be based on universally approved biological markers (eg CD markers) and purity should always be checked, preferably by flow cytometry. Furthermore, in order to compare separate cell samples, they should preferably be collected from comparable tissue types, at identical locations in the body, and under comparable circumstances.
These guidelines can help to conduct microarray experiments in a meaningful way and to provide the clinical and research community with reliable results.
